Microvast Holdings announces departure of chief financial officer
Investing.com - Cantor Fitzgerald maintained its Neutral rating on Prothena Corp (NASDAQ:PRTA), currently trading at $5.75, following the company’s announcement of a corporate restructuring plan after discontinuing its birtamimab Phase 3 trial. According to InvestingPro analysis, the stock appears undervalued based on its Fair Value assessment.
The restructuring follows the May termination of the AFFIRM-AL trial, which failed to demonstrate a survival benefit for birtamimab in AL amyloidosis patients. Prothena decided to halt birtamimab development entirely and significantly reduce operating expenses to preserve cash. The company maintains a strong liquidity position with a current ratio of 9.0, though its stock has declined 58% year-to-date.
As part of the cost-cutting measures, Prothena is reducing its workforce by approximately 63%, leaving the company with around 60 full-time employees after the restructuring is completed.
Prothena projects its net cash burn to be approximately $170-$178 million in 2025, with the company expected to end 2025 with approximately $298 million in cash. Going forward, annual net cash burn is anticipated to be around $60-$70 million.
The company could potentially earn up to $105 million in clinical milestone payments between now and 2026, assuming partners proceed with certain programs, which would provide immediate cash for Prothena as it evaluates strategies to maximize the value of its remaining assets. Get deeper insights into Prothena’s financial health and growth prospects with InvestingPro’s comprehensive research report, one of 1,400+ available for top US stocks.
In other recent news, Prothena Corporation announced a significant 63% reduction in its workforce as part of a strategic review aimed at reducing operating costs and supporting its core programs. The company revised its 2025 financial guidance, projecting a net cash burn of $170 to $178 million and a year-end cash position of approximately $298 million. Prothena also disclosed an expected net loss of $240 to $248 million for 2025, influenced by non-cash expenses. In a separate development, Prothena’s partner Roche advanced prasinezumab into Phase 3 development for early-stage Parkinson’s disease, following promising Phase 2b results. This milestone reflects potential long-term value for Prothena, despite the recent setback with birtamimab. Analyst firm Oppenheimer maintained its Perform rating on Prothena, while BofA Securities downgraded the stock from Neutral to Underperform, citing birtamimab’s failure in a crucial trial. Piper Sandler also adjusted its price target for Prothena, lowering it from $110 to $81, but maintained an Overweight rating due to potential upcoming clinical data for PRX012. Prothena’s partnerships with companies like Novo Nordisk (NYSE:NVO) and Bristol Myers (NYSE:BMY) Squibb may yield up to $105 million in clinical milestone payments by 2026.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.